teriflunomide krka 14 mg tabletti, kalvopäällysteinen
krka, d.d., novo mesto - teriflunomide - tabletti, kalvopäällysteinen - 14 mg - teriflunomidi
teriflunomide avansor 14 mg tabletti, kalvopäällysteinen
avansor pharma oy - teriflunomide - tabletti, kalvopäällysteinen - 14 mg - teriflunomidi
teriflunomide orion 14 mg tabletti, kalvopäällysteinen
orion corporation - teriflunomide - tabletti, kalvopäällysteinen - 14 mg - teriflunomidi
fingolimod krka 0.5 mg kapseli, kova
krka, d.d., novo mesto - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi
tyruko
sandoz gmbh - natalitsumabin - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressantit - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ja 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.